INSR
INSR encodes the insulin receptor, a receptor tyrosine kinase that binds insulin and initiates the intracellular signaling cascades (via IRS proteins and PI3K/AKT) responsible for glucose homeostasis, lipid metabolism, and growth. Severe INSR mutations cause extreme insulin resistance syndromes, while milder dysregulation contributes to type 2 diabetes.
Key Takeaways
- •INSR is a receptor tyrosine kinase that serves as the universal cellular "lock" for the hormone insulin.
- •Its activation triggers IRS phosphorylation, initiating the PI3K/AKT pathway for metabolism and the MAPK pathway for growth.
- •Severe genetic mutations in INSR cause extreme insulin resistance syndromes (e.g., Donohue syndrome).
- •Common Type 2 Diabetes is characterized by acquired "post-receptor" defects in INSR signaling caused by obesity and inflammation.
Basic Information
- Gene Symbol
- INSR
- Full Name
- Insulin Receptor
- Also Known As
- CD220HHF5
- Location
- 19p13.2
- Protein Type
- Receptor Tyrosine Kinase (RTK)
- Protein Family
- Insulin Receptor Family
Related Isoforms
Exon 11 excluded. Fetal and cancer form. High affinity for IGF-2; drives mitogenesis.
Exon 11 included. Classic adult metabolic form. Expressed in liver, muscle, and fat.
Key SNPs
Polymorphism occasionally studied in association with insulin resistance and PCOS.
Associated with altered fasting insulin levels and HOMA-IR in some cohorts.
Synonymous variant used in haplotype analysis for T2D susceptibility.
May influence INSR mRNA stability; linked to PCOS risk in specific populations.
Associated with longevity and metabolic health in certain centenarian cohorts.
Overview
The INSR gene encodes the insulin receptor, a master regulatory transmembrane protein that controls systemic energy metabolism. Structurally, INSR is a heterotetramer composed of two extracellular alpha-subunits (which bind insulin) and two transmembrane beta-subunits (which contain the intrinsic tyrosine kinase activity). Disulfide bonds link these subunits into a functional functional α2β2 complex.
When insulin binds to the alpha-subunits, it causes a conformational change that brings the intracellular beta-subunits together, triggering auto-phosphorylation. This active kinase then phosphorylates intracellular docking proteins—most notably the Insulin Receptor Substrate (IRS) family—which serve as scaffolds to activate the PI3K/AKT and MAPK pathways.
Conceptual Model
A simplified mental model for the pathway:
Insulin binding relief inhibitory constraint on the kinase domain.
Core Health Impacts
- • Energy metabolism: Mediates all metabolic effects of insulin in liver, muscle, and adipose tissue.
- • Insulin sensitivity: Healthy function prevents insulin resistance, the root of metabolic syndrome.
- • Mitogenesis: INSR-A isoform drives growth and proliferation in fetal development and cancer.
- • Vascular tone: Regulates vascular tone by activating eNOS via the AKT pathway.
Protein Domains
Alpha Subunits
Entirely extracellular; contain the insulin binding sites. Mutations here generally impair ligand affinity.
Beta Subunits
Span the membrane; contain the tyrosine kinase domain responsible for signal transduction.
Activation Loop
Region within the kinase domain where phosphorylation of three specific tyrosines triggers full activity.
Upstream Regulators
Insulin Activator
The primary physiological ligand; binds the alpha-subunits to activate the kinase domain.
IGF-2 Activator
Binds with high affinity to the INSR-A isoform, driving mitogenic pathways in development.
IGF-1 Activator
Can bind INSR with lower affinity; also forms INSR/IGF1R heterodimers.
PTP1B Inhibitor
Protein Tyrosine Phosphatase 1B actively dephosphorylates INSR to turn it off.
Downstream Targets
IRS-1 / IRS-2 Activates
Docking proteins phosphorylated by INSR to recruit PI3K and other SH2-domain proteins.
PI3K Activates
Recruited by IRS proteins to initiate the AKT survival and metabolic cascade.
Shc Activates
Adaptor protein that links the receptor to the Ras/MAPK pathway for growth signaling.
CAP Activates
Part of a PI3K-independent pathway involving TC10 for GLUT4 vesicle translocation.
FoxO Factors Inhibits
Inhibited via the PI3K/AKT axis to suppress gluconeogenesis.
mTORC1 Activates
Activated downstream of the INSR/AKT cascade to drive protein synthesis.
Role in Aging
The insulin/IGF-1 signaling (IIS) pathway via INSR and IGF1R is a master regulator of lifespan. Paradoxically, while healthy insulin sensitivity is a hallmark of youth, genetic models show that reducing total INSR signaling extends lifespan.
DAF-2 Homology
In C. elegans, DAF-2 is the sole ortholog of INSR/IGF1R. Reducing its function can double lifespan by activating DAF-16/FOXO.
FIRKO Model
Mice lacking INSR specifically in adipose tissue (FIRKO) are lean and live 18% longer than wild-type controls.
Proteostasis
Robust INSR activation drives mTORC1, which suppresses the autophagy necessary to clear damaged proteins with age.
Centenarian Paradox
Some centenarians carry rare INSR mutations that reduce signaling, achieving a "sweet spot" of sensitivity without over-activation.
Receptor Internalization
Chronic hyperinsulinemia leads to decreased surface INSR levels via internalization, contributing to metabolic aging.
Neurodegeneration
Synaptic plasticity depends on INSR. Brain-specific insulin resistance is heavily implicated in Alzheimer’s pathology.
Disorders & Diseases
Type 2 Diabetes
Usually characterized by "post-receptor" defects. Inflammation and lipids trigger serine phosphorylation of INSR/IRS, jamming the signal.
Donohue Syndrome
Severe recessive mutations leading to near-total loss of function. Characterized by extreme resistance and intrauterine growth restriction.
Rabson-Mendenhall Syndrome
Less severe than Donohue; patients survive past infancy but develop severe diabetes and skin anomalies like acanthosis nigricans.
Type A Insulin Resistance
Dominant-negative mutations in the kinase domain. Presents in young, non-obese women with severe resistance and hyperandrogenism.
Cancer
Upregulation of the fetal INSR-A isoform creates autocrine loops with IGF-2 to drive proliferation and resistance to apoptosis.
Interventions
Supplements
May enhance the tyrosine kinase activity of the receptor or improve downstream signaling.
Antioxidant that may protect INSR components from oxidative stress and improve glucose uptake.
Myo- and D-chiro inositol function as downstream second messengers in the insulin cascade.
Help maintain membrane fluidity, essential for INSR mobility, dimerization, and endocytosis.
Lifestyle
Reduces inflammatory cytokines (TNF-α) that cause serine phosphorylation and INSR jamming.
Activates AMPK to bypass INSR for glucose uptake while improving long-term receptor sensitivity.
Reducing saturated fats prevents ceramide accumulation that inhibits INSR signaling via PKC.
Lowers basal insulin, preventing INSR downregulation and resensitizing the cellular receptor pool.
Medicines
PPAR-γ agonists (like Pioglitazone) that alter adipokine profiles to enhance systemic INSR sensitivity.
Improves hepatic insulin sensitivity primarily via AMPK, indirectly supporting INSR function.
Directly binds and activates INSR when endogenous production is insufficient.
Used in severe INSR mutations (Donohue syndrome) to signal through the intact IGF1R pathway.
Lab Tests & Biomarkers
Genetic Testing
Used to diagnose severe congenital insulin resistance syndromes like Donohue or Type A.
Activity Markers
Clinical skin marker of extreme hyperinsulinemia cross-reacting with IGF-1 receptors.
Low Sex Hormone Binding Globulin is a biomarker of hepatic insulin resistance.
Metabolic Markers
Elevated levels indicate failure of INSR signaling, forcing beta-cell over-secretion.
Mathematical model using fasting glucose and insulin to quantify systemic resistance.
Hormonal Interactions
Insulin Primary Agonist
Binds INSR to orchestrate the entire postprandial anabolic response.
Adiponectin Sensitizer
Adipokine that strongly enhances INSR signaling efficiency and promotes fat oxidation.
Resistin Antagonist
Obesity-associated adipokine that directly impairs INSR signaling.
Cortisol Antagonist
Induces post-receptor insulin resistance by altering IRS-1 phosphorylation.
Growth Hormone Modulator
Decreases peripheral INSR sensitivity while relying on the pathway for growth effects.
Deep Dive
Network Diagrams
INSR Divergent Signaling
INSR Isoform Affinities
Receptor Activation and Divergent Signaling
INSR operates as an allosteric enzyme. In the unbound state, the extracellular alpha-subunits exert an inhibitory constraint on the intracellular beta-subunits. When insulin binds, this constraint is relieved. The beta-subunits trans-autophosphorylate each other on specific tyrosine residues within the activation loop.
This active kinase then phosphorylates IRS proteins. The phosphorylation of IRS creates docking sites for SH2-domain containing proteins, splitting the signal into two primary arms:
-
The Metabolic Arm (PI3K/AKT): IRS binds PI3K, generating PIP3, which activates AKT. This drives glucose uptake (GLUT4 translocation), glycogen synthesis, and lipogenesis. This arm is highly susceptible to obesity-induced insulin resistance.
-
The Mitogenic Arm (Ras/MAPK): IRS (or Shc) binds Grb2/SOS, activating the Ras/MAPK cascade. This drives gene expression, cell growth, and proliferation. Crucially, this arm often remains sensitive even when the metabolic arm is resistant, leading to pathological hyper-proliferation (e.g., vascular smooth muscle growth) during the hyperinsulinemia of T2D.
The Mechanism of Insulin Resistance
Common insulin resistance is not a genetic defect in INSR, but a biochemical blockade. Ectopic fat accumulation (lipotoxicity) generates diacylglycerols (DAG) and ceramides. Simultaneously, hypertrophic adipocytes release inflammatory cytokines like TNF-α.
These stress signals activate serine/threonine kinases (PKCθ, JNK, IKK). These kinases phosphorylate the INSR and IRS-1 on serine residues instead of the necessary tyrosine residues. Serine phosphorylation sterically hinders the interaction between INSR and IRS, and promotes IRS degradation.
The receptor is essentially “jammed” from the inside out. Insulin binds, but the signal cannot pass through the IRS node to PI3K. This forces the pancreas to pump out ever-increasing amounts of insulin to force the signal through the blockade.
INSR Isoforms: Metabolic vs. Mitogenic Receptors
Alternative splicing of exon 11 generates two functionally distinct isoforms of the insulin receptor.
INSR-B (Exon 11+): The classic metabolic receptor. It has high affinity for insulin and very low affinity for IGF-2. It is predominantly expressed in the major metabolic tissues: liver, muscle, and adipose. It prioritizes the PI3K/AKT pathway.
INSR-A (Exon 11-): The mitogenic receptor. It has high affinity for both insulin and IGF-2. It is predominantly expressed during fetal development. Many cancer cells aberrantly undergo splicing shifts to re-express INSR-A, hijacking it to respond to autocrine IGF-2 and drive tumor proliferation via the MAPK pathway.
Relevant Research Papers
Links go to PubMed (abstracts are public); some papers also offer free full text via PMC or the publisher.
First cloning of the human insulin receptor cDNA, revealing homology to other RTKs.
The human insulin receptor cDNA: the structural basis for hormone-activated transmembrane signalling
Demonstrated the intrinsic tyrosine kinase activity of INSR upon insulin binding.
Classic review of how INSR mutations cause extreme insulin resistance syndromes.
Comprehensive overview of INSR structure, signaling, and role in metabolic syndrome.
Established INSR-A as a functional receptor for IGF-2 in development and cancer.
Detailed the post-receptor INSR defects (serine phosphorylation) characterizing PCOS.